On Friday the Vetr crowd downgraded their rating for Regeneron Pharmaceuticals Inc REGN from 4.5 stars (Strong Buy), issued 80 days ago, to 4 stars (Buy). At the time of the downgrade, crowd confidence in Regeneron was mostly positive, with 85 percent of Vetr user ratings bullish.
The biopharmaceutical company has been trending up the past couple of weeks after dipping below $350 earlier in the year. The stock has gained more than 8 percent since the tail end of February, hitting a three-month high of 392.08 on March 9. The recent price gain earned Regeneron an initiation from UBS at Buy.
Learn how crowdsourced ratings could help you time the market.
Currently, the Vetr crowd's average target price for Regeneron is up at $434.63, which is still below the average analyst target price of $449.52. Less than 2 percent of Vetr users are holding REGN in their watch lists.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
